Bay Colony Advisory Group Inc d b a Bay Colony Advisors Makes New Investment in Revolution Medicines, Inc. $RVMD

Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 5,050 shares of the company’s stock, valued at approximately $236,000.

A number of other large investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Revolution Medicines by 0.3% during the 2nd quarter. California State Teachers Retirement System now owns 140,077 shares of the company’s stock worth $5,153,000 after buying an additional 437 shares in the last quarter. CWM LLC lifted its position in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company’s stock worth $34,000 after buying an additional 579 shares in the last quarter. Avanza Fonder AB boosted its stake in shares of Revolution Medicines by 17.5% in the 3rd quarter. Avanza Fonder AB now owns 4,335 shares of the company’s stock worth $202,000 after buying an additional 647 shares during the last quarter. Finally, Voya Investment Management LLC grew its holdings in shares of Revolution Medicines by 2.0% in the third quarter. Voya Investment Management LLC now owns 47,534 shares of the company’s stock valued at $2,220,000 after acquiring an additional 921 shares in the last quarter. 94.34% of the stock is owned by institutional investors.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 75,000 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total transaction of $7,542,000.00. Following the sale, the chief operating officer owned 141,053 shares of the company’s stock, valued at $14,184,289.68. The trade was a 34.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark A. Goldsmith sold 60,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $75.08, for a total value of $4,504,800.00. Following the sale, the insider owned 247,863 shares in the company, valued at approximately $18,609,554.04. This represents a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 243,792 shares of company stock valued at $19,757,740 over the last 90 days. 8.20% of the stock is currently owned by corporate insiders.

Revolution Medicines Price Performance

NASDAQ RVMD opened at $117.17 on Tuesday. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. The company has a market cap of $22.65 billion, a PE ratio of -22.66 and a beta of 0.99. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $121.61. The firm’s 50-day simple moving average is $77.52 and its two-hundred day simple moving average is $54.75.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same quarter in the prior year, the company earned ($0.94) EPS. Research analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. UBS Group raised Revolution Medicines to a “strong-buy” rating in a research report on Thursday, December 4th. Royal Bank Of Canada assumed coverage on Revolution Medicines in a research note on Monday, November 3rd. They issued an “outperform” rating and a $77.00 price objective for the company. Wolfe Research started coverage on Revolution Medicines in a research report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 target price for the company. HC Wainwright raised their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Mizuho began coverage on shares of Revolution Medicines in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $90.00 price objective on the stock. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.